UK patented-pharma Section 232 rate falls from 10% to 0%
Commerce reduced the additional tariff on covered patented pharmaceutical articles and associated ingredients that are products of the United Kingdom from 10% to 0%. CBP says the change applies under HTSUS 9903.04.63 to entries and warehouse withdrawals from 12:01 a.m. Eastern Time on July 31 and that ACE is updated.
- Impact score
- 74/100
- Confidence
- Confirmed · 55%
- Official sources
- 3
- First seen
Editorially verified brief
CheckedThe Commerce Department's Bureau of Industry and Security reduced the Section 232 additional tariff on patented pharmaceuticals and associated pharmaceutical ingredients that are products of the United Kingdom from 10 percent to zero percent. The change is effective for covered goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. Eastern Time on July 31, 2026.
The Commerce notice implements the UK treatment contemplated by Presidential Proclamation 11020. It states that the United States and United Kingdom concluded a pharmaceutical-pricing arrangement and that the arrangement's relevant requirements are currently being met. The notice amends HTSUS heading 9903.04.63 by replacing “+10%” with “+0%.”
CBP issued operational guidance on August 1 and says it has completed the necessary Automated Commercial Environment updates. CBP instructs importers, brokers, and filers to use heading 9903.04.63 for patented pharmaceutical articles that are products of the United Kingdom as defined in U.S. note 40(c) and (g) to subchapter III. The corresponding additional ad valorem duty rate is zero percent for qualifying entries from the July 31 effective time.
The zero additional rate is limited to merchandise that meets the operative product, origin, and note definitions. CBP directs filers to its earlier Section 232 pharmaceutical guidance for the Chapter 1 through 97 classifications corresponding to heading 9903.04.63 and the other headings established by Proclamation 11020.
Action items
- Identify patented pharmaceutical articles and associated ingredients that are products of the United Kingdom and were entered or withdrawn from warehouse on or after the July 31 effective time.
- Validate the ordinary Chapter 1 through 97 classification and the definitions in U.S. note 40 before using heading 9903.04.63.
- Configure qualifying entry lines with the zero percent additional rate and follow CBP's prescribed Chapter 98 and Chapter 99 reporting sequence.
- Review entries filed since the effective time for an incorrect 10 percent assessment and coordinate any needed correction with the customs broker, CBP client representative, or ACE Help Desk.
- Continue checking for other ordinary, trade-remedy, or special duties that may apply; the notice changes this Section 232 rate rather than declaring the merchandise free of every duty.
Why it matters
The reduction directly changes entry treatment for covered UK-origin pharmaceuticals, but it does not make every pharmaceutical product duty-free. Importers still need the Chapter 1–97 classification, the definitions in U.S. note 40, and the applicable Chapter 99 reporting sequence.
What to check next
Map UK-origin patented pharmaceuticals and associated ingredients to CBP's Chapter 1–97 list and U.S. note 40, report HTSUS 9903.04.63 at the 0% additional rate for qualifying entries from July 31, and review entries filed since the effective time for any incorrect 10% assessment that should be raised with your broker or CBP.
Primary sources
Does this matter to your operation?
Your answer tunes the For you view on this device. It does not change the facts or the verification status.
Affected
Provenance
- First detected
- Official source published
- Editorial review completed
- Latest update
Score breakdown
How scores work: methodology.